These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12061944)

  • 101. [Why is the number increasing? A new method explains the changes in mortality from Parkinson disease and ALS].
    Conradi S
    Lakartidningen; 1994 Sep; 91(39):3487-90. PubMed ID: 7990585
    [No Abstract]   [Full Text] [Related]  

  • 102. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis.
    Körner S; Kollewe K; Ilsemann J; Müller-Heine A; Dengler R; Krampfl K; Petri S
    Eur J Neurol; 2013 Apr; 20(4):647-54. PubMed ID: 23094606
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Regional spread pattern predicts survival in patients with sporadic amyotrophic lateral sclerosis.
    Gargiulo-Monachelli GM; Janota F; Bettini M; Shoesmith CL; Strong MJ; Sica RE
    Eur J Neurol; 2012 Jun; 19(6):834-41. PubMed ID: 22248150
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis.
    Qureshi M; Shui A; Dibernardo AB; Brown RH; Schoenfeld DA; Cudkowicz ME
    Amyotroph Lateral Scler; 2008 Dec; 9(6):369-74. PubMed ID: 18608098
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Prognostic value of clinical and electrodiagnostic parameters at time of diagnosis in patients with amyotrophic lateral sclerosis.
    Reniers W; Schrooten M; Claeys KG; Tilkin P; D'Hondt A; Van Reijen D; Couwelier G; Lamaire N; Robberecht W; Fieuws S; Van Damme P
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Aug; 18(5-6):341-350. PubMed ID: 28631957
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis.
    Ackrivo J; Hansen-Flaschen J; Wileyto EP; Schwab RJ; Elman L; Kawut SM
    Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30728207
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Epidemiological and clinical factors impact on the benefit of riluzole in the survival rates of patients with ALS.
    Fávero FM; Voos MC; Castro I; Caromano FA; Oliveira ASB
    Arq Neuropsiquiatr; 2017 Aug; 75(8):515-522. PubMed ID: 28813081
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci.
    Messori A; Trippoli S; Becagli P; Zaccara G
    Pharmacoeconomics; 1999 Aug; 16(2):153-63. PubMed ID: 10539396
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Factors predicting survival in ALS: a multicenter Italian study.
    Calvo A; Moglia C; Lunetta C; Marinou K; Ticozzi N; Ferrante GD; Scialo C; Sorarù G; Trojsi F; Conte A; Falzone YM; Tortelli R; Russo M; Chiò A; Sansone VA; Mora G; Silani V; Volanti P; Caponnetto C; Querin G; Monsurrò MR; Sabatelli M; Riva N; Logroscino G; Messina S; Fini N; Mandrioli J
    J Neurol; 2017 Jan; 264(1):54-63. PubMed ID: 27778156
    [TBL] [Abstract][Full Text] [Related]  

  • 110. A predictive model for amyotrophic lateral sclerosis (ALS) diagnosis.
    Gupta PK; Prabhakar S; Sharma S; Anand A
    J Neurol Sci; 2012 Jan; 312(1-2):68-72. PubMed ID: 21907354
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone disease.
    Forbes RB; Colville S; Cran GW; Swingler RJ;
    J Neurol Neurosurg Psychiatry; 2004 Dec; 75(12):1753-5. PubMed ID: 15548498
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Endogenous progesterone is associated to amyotrophic lateral sclerosis prognostic factors.
    Gargiulo Monachelli G; Meyer M; Rodríguez GE; Garay LI; Sica RE; De Nicola AF; González Deniselle MC
    Acta Neurol Scand; 2011 Jan; 123(1):60-7. PubMed ID: 20545634
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study.
    Zoccolella S; Beghi E; Palagano G; Fraddosio A; Guerra V; Samarelli V; Lepore V; Simone IL; Lamberti P; Serlenga L; Logroscino G;
    J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):33-7. PubMed ID: 17550991
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics.
    Rudnicki SA; Berry JD; Ingersoll E; Archibald D; Cudkowicz ME; Kerr DA; Dong Y
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Jan; 14(1):44-51. PubMed ID: 22985432
    [TBL] [Abstract][Full Text] [Related]  

  • 115. A clinical tool for predicting survival in ALS.
    Knibb JA; Keren N; Kulka A; Leigh PN; Martin S; Shaw CE; Tsuda M; Al-Chalabi A
    J Neurol Neurosurg Psychiatry; 2016 Dec; 87(12):1361-1367. PubMed ID: 27378085
    [TBL] [Abstract][Full Text] [Related]  

  • 116. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS.
    Bozik ME; Mitsumoto H; Brooks BR; Rudnicki SA; Moore DH; Zhang B; Ludolph A; Cudkowicz ME; van den Berg LH; Mather J; Petzinger T; Archibald D
    Amyotroph Lateral Scler Frontotemporal Degener; 2014 Sep; 15(5-6):406-13. PubMed ID: 25125035
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Associations between co-medications and survival in ALS-a cohort study from Austria.
    Cetin H; Klickovic U; Rath J; Zulehner G; Füzi J; Reichardt B; Hagmann M; Wanschitz J; Löscher WN; Auff E; Zimprich F
    J Neurol; 2015 Jul; 262(7):1698-705. PubMed ID: 25957641
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Would riluzole be efficacious in the new ALS trial design?
    Verstraete E; Veldink JH; van den Berg LH
    Lancet Neurol; 2010 Oct; 9(10):949-50; author reply 950-1. PubMed ID: 20864047
    [No Abstract]   [Full Text] [Related]  

  • 119. Prognosis in amyotrophic lateral sclerosis: a population-based study.
    del Aguila MA; Longstreth WT; McGuire V; Koepsell TD; van Belle G
    Neurology; 2003 Mar; 60(5):813-9. PubMed ID: 12629239
    [TBL] [Abstract][Full Text] [Related]  

  • 120. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II.
    Lacomblez L; Bensimon G; Leigh PN; Guillet P; Powe L; Durrleman S; Delumeau JC; Meininger V
    Neurology; 1996 Dec; 47(6 Suppl 4):S242-50. PubMed ID: 8959996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.